The Lysophosphatidic Acid (LPA) Assay Kit II is a sensitive, specific, and robust method for quantification of LPA in Plasma, Serum, and Tissue Homogenate.
Sample Types: Serum, Plasma, and Tissue homogenate (human or animal)
Sample Volume: 20 µL/sample (for duplicate points)
Assay Incubation Time: 2 hours and 30 minutes
Assay Range: 0.064 µM to 1,000 µM
The Lysophosphatidic Acid (LPA) Assay is an ELISA designed for the in vitro measurement of Lysophosphatidic Acid (LPA) in biological samples. The LPA Assay is specific for LPA and sensitive to the different acyl chains. The assay is a competitive ELISA in which the colorimetric signal is inversely proportional to the amount of LPA present in the sample. Essentially, as LPA is increased in the assay the colorimetric signal is reduced. Briefly, the scientist will mix their samples with the biotinylated anti-LPA antibody and a sample diluent. Then they transfer the mixtures to the LPA coated detection plate for competitive binding. Streptavidin-HRP and colorimetric detection are used to detect the amount of biotinylated anti-LPA bound to the plate. The concentration of LPA in the sample is determined using a standard curve of known amounts of LPA. The LPA Assay is read at 450 nm and requires 3 hours to run.
LPA is a serum-derived phospholipid involved in diverse cellular processes such as cell proliferation, chemotaxis, platelet aggregation, wound healing, angiogenesis, tumor invasion, and smooth muscle contraction. Recent research indicates LPA may play a significant role in the pathophysiology of cancer and may be used as a biomarker for ovarian cancer.
Keywords: K-2800, K-2800B, LPA ELISA, LPA detection, Autotaxin, ATX